GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Panacea Biotec Ltd (BOM:531349) » Definitions » Cash Conversion Cycle

Panacea Biotec (BOM:531349) Cash Conversion Cycle : 82.89 (As of Mar. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Panacea Biotec Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Panacea Biotec's Days Sales Outstanding for the three months ended in Mar. 2024 was 38.4.
Panacea Biotec's Days Inventory for the three months ended in Mar. 2024 was 326.37.
Panacea Biotec's Days Payable for the three months ended in Mar. 2024 was 281.88.
Therefore, Panacea Biotec's Cash Conversion Cycle (CCC) for the three months ended in Mar. 2024 was 82.89.


Panacea Biotec Cash Conversion Cycle Historical Data

The historical data trend for Panacea Biotec's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Panacea Biotec Cash Conversion Cycle Chart

Panacea Biotec Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only -196.90 -53.50 -11.44 58.24 77.23

Panacea Biotec Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 81.85 83.64 88.67 80.85 82.89

Competitive Comparison of Panacea Biotec's Cash Conversion Cycle

For the Biotechnology subindustry, Panacea Biotec's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Panacea Biotec's Cash Conversion Cycle Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Panacea Biotec's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Panacea Biotec's Cash Conversion Cycle falls into.



Panacea Biotec Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Panacea Biotec's Cash Conversion Cycle for the fiscal year that ended in Mar. 2024 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=38.35+301.39-262.51
=77.23

Panacea Biotec's Cash Conversion Cycle for the quarter that ended in Mar. 2024 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=38.4+326.37-281.88
=82.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Panacea Biotec  (BOM:531349) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Panacea Biotec Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Panacea Biotec's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Panacea Biotec (BOM:531349) Business Description

Traded in Other Exchanges
Address
Mathura Road, B-1 Extn./G-3, Mohan Co-operative Industrial Estate, New Delhi, IND, 110 044
Panacea Biotec Ltd is a Biotechnology company. It is engaged in the business of research, development, manufacturing, and marketing of branded pharmaceutical formulations, vaccines, and biopharmaceuticals. The company's operating segments include Vaccines, and Formulations. It generates maximum revenue from the Vaccines segment. The company product portfolio includes prescription products in niche therapeutic areas such as diabetes and cardiovascular management, oncology, nephrology and transplant management, osteoporosis management, gastro-intestinal care, pain management products, and pediatric immunization. The group has a business presence in India and Outside India.

Panacea Biotec (BOM:531349) Headlines

No Headlines